232 related articles for article (PubMed ID: 21791470)
1. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.
van Duin M; Broyl A; de Knegt Y; Goldschmidt H; Richardson PG; Hop WC; van der Holt B; Joseph-Pietras D; Mulligan G; Neuwirth R; Sahota SS; Sonneveld P
Haematologica; 2011 Nov; 96(11):1662-9. PubMed ID: 21791470
[TBL] [Abstract][Full Text] [Related]
2. The role of Cancer/Testis Antigens in Multiple Myeloma pathogenesis and their application in disease monitoring and therapy.
Shires K; Van Wyk T
Crit Rev Oncol Hematol; 2018 Dec; 132():17-26. PubMed ID: 30447924
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.
Andrade VC; Vettore AL; Felix RS; Almeida MS; Carvalho F; Oliveira JS; Chauffaille ML; Andriolo A; Caballero OL; Zago MA; Colleoni GW
Cancer Immun; 2008 Feb; 8():2. PubMed ID: 18237105
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
[TBL] [Abstract][Full Text] [Related]
5. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.
Taylor BJ; Reiman T; Pittman JA; Keats JJ; de Bruijn DR; Mant MJ; Belch AR; Pilarski LM
J Immunother; 2005; 28(6):564-75. PubMed ID: 16224274
[TBL] [Abstract][Full Text] [Related]
6. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis.
Condomines M; Hose D; Raynaud P; Hundemer M; De Vos J; Baudard M; Moehler T; Pantesco V; Moos M; Schved JF; Rossi JF; Rème T; Goldschmidt H; Klein B
J Immunol; 2007 Mar; 178(5):3307-15. PubMed ID: 17312182
[TBL] [Abstract][Full Text] [Related]
7. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.
Atanackovic D; Hildebrandt Y; Jadczak A; Cao Y; Luetkens T; Meyer S; Kobold S; Bartels K; Pabst C; Lajmi N; Gordic M; Stahl T; Zander AR; Bokemeyer C; Kröger N
Haematologica; 2010 May; 95(5):785-93. PubMed ID: 20015885
[TBL] [Abstract][Full Text] [Related]
8. [Reseach Advances on Cancer-Testis Antigens in Multiple Myeloma -Review].
Yang ZR; Yu L; Zhu HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):296-300. PubMed ID: 28245420
[TBL] [Abstract][Full Text] [Related]
9. Expression of cancer-testis antigen in multiple myeloma.
He L; Ji JN; Liu SQ; Xue E; Liang Q; Ma Z
J Huazhong Univ Sci Technolog Med Sci; 2014 Apr; 34(2):181-185. PubMed ID: 24710929
[TBL] [Abstract][Full Text] [Related]
10. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens.
Ghafouri-Fard S; Seifi-Alan M; Shamsi R; Esfandiary A
Iran J Cancer Prev; 2015 Oct; 8(5):e3755. PubMed ID: 26634107
[TBL] [Abstract][Full Text] [Related]
13. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy.
Chiriva-Internati M; Mirandola L; Yu Y; Jenkins MR; Gornati R; Bernardini G; Gioia M; Chiaramonte R; Cannon MJ; Kast WM; Cobos E
J Immunother; 2011; 34(6):490-9. PubMed ID: 21654522
[TBL] [Abstract][Full Text] [Related]
14. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
Bodey B
Expert Opin Biol Ther; 2002 Aug; 2(6):577-84. PubMed ID: 12171503
[TBL] [Abstract][Full Text] [Related]
15. Serum Lactate Dehydrogenase Can Be Used as a Factor for Re-Evaluating First-Relapsed Multiple Myeloma.
Liu Y; Wen L; Chen H; Chen Y; Duan W; Kang Y; Ma L; Huang X; Lu J
Acta Haematol; 2020; 143(6):559-566. PubMed ID: 32610311
[TBL] [Abstract][Full Text] [Related]
16. High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.
Wen J; Li H; Tao W; Savoldo B; Foglesong JA; King LC; Zu Y; Chang CC
Br J Haematol; 2014 Sep; 166(5):711-9. PubMed ID: 24889268
[TBL] [Abstract][Full Text] [Related]
17. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.
Seckinger A; Meissner T; Moreaux J; Goldschmidt H; Fuhler GM; Benner A; Hundemer M; Rème T; Shaughnessy JD; Barlogie B; Bertsch U; Hillengass J; Ho AD; Pantesco V; Jauch A; De Vos J; Rossi JF; Möhler T; Klein B; Hose D
Oncogene; 2009 Nov; 28(44):3866-79. PubMed ID: 19718049
[TBL] [Abstract][Full Text] [Related]
18. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.
Hermansen NE; Borup R; Andersen MK; Vangsted AJ; Clausen NT; Kristensen DL; Nielsen FC; Gimsing P
Int J Lab Hematol; 2016 Jun; 38(3):298-307. PubMed ID: 27027250
[TBL] [Abstract][Full Text] [Related]
19. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
20. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma.
Atanackovic D; Blum I; Cao Y; Wenzel S; Bartels K; Faltz C; Hossfeld DK; Hegewisch-Becker S; Bokemeyer C; Leuwer R
Cancer Biol Ther; 2006 Sep; 5(9):1218-25. PubMed ID: 16929165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
